Search Results - peptide+inhibitor

4 Results Sort By:
A Novel Genetically Encoded Inhibitor of Hippo Signaling Pathway to Study YAP1/TAZ-TEAD Dependent Events in Cancer
Summary: The NCI Laboratory of Cellular and Molecular Biology seeks statements of capability or interest from parties interested in licensing this novel inhibitor of the Hippo signaling pathway. Description of Technology: The Hippo signaling pathway regulates a multitude of biological processes including cell proliferation, apoptosis, differentiation,...
Published: 4/24/2026   |   Updated: 8/2/2023   |   Inventor(s): Ramiro Iglesias-Bartolome, Yao Yuan
Keywords(s): Cancer Progression, Hippo Signaling Pathway, Iglesias-Bartolome, Peptide Inhibitor, TAZ, TEAD, YAP1, Yes-Associated Protein 1
Category(s): TherapeuticArea > Oncology, Application > Research Materials, Collaboration Sought > Licensing
Peptide Mimetic Ligands of Polo-like Kinase 1 Polo Box Domain
Abstract: Polo-like kinase 1 (Plk1) is a critical protein involved in regulation of mitosis, and aberrant expression of this kinase is found in various cancer types.  Inhibition of Plk1 is currently being pursued in pre-clinical drug development for novel anti-cancer therapeutics.  Plk1 contains an allosteric domain, known as the polo-box domain (PBD),...
Published: 4/22/2025   |   Updated: 8/2/2023   |   Inventor(s): Terrence Burke, Wen-Jian Qian, Kyung Lee, Jung-Eun Park, James Kelley
Keywords(s): Burke, CANCER, mitosis, Peptide Inhibitor, polo-box domain (PBD), Polo-like kinase 1 (Plk1), therapeutic
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics
Peptide Mimetic Ligands of Polo-like Kinase 1 Polo Box Domain (“Plk1 PBD Portfolio”)
Abstract: Polo-like kinase 1 (Plk1) is a critical protein involved in regulation of mitosis, and aberrant expression of this kinase is found in various cancer types.  Inhibition of Plk1 is currently being pursued in pre-clinical drug development for novel anti-cancer therapeutics.  Plk1 contains an allosteric domain, known as the polo-box domain (PBD),...
Published: 4/22/2025   |   Updated: 8/2/2023   |   Inventor(s): Terrence Burke, Jung-Eun Park, Wen-Jian Qian, Fa Liu, Kyung Lee
Keywords(s): Burke, CANCER, mitosis, Peptide Inhibitor, polo-box domain (PBD), Polo-like kinase 1 (Plk1), therapeutic
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics
Hydrocarbon Stapled Peptides that Inhibit the Linear Ubiquitin Chain Assembly Complex (LUBAC) for the Therapy of the Activated B Cell-like (ABC) Subtype of Diffuse Large B Bell Lymphoma (A Type of Non-Hodgkin’s Lymphoma)
Abstract: Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin’s lymphoma and consists of three subtypes: activated B-cell (ABC), germinal center B-cell (GBC), and primary mediastinal B-cell (PMB). Despite advances in the front-line therapy for DLBCL, approximately one-third of patients will relapse. Substantially worse outcomes...
Published: 4/22/2025   |   Updated: 8/2/2023   |   Inventor(s): Louis Staudt, Yiban Yang, Federico Bernal
Keywords(s): ABC DLBCL, Activated B Cell-like, Autoimmune, Bernal, CANCER, Diffuse Large B Cell Lymphoma, INFLAMMATORY, Linear Ubiquitin-chain Assembly Complex, LUBAC, NF-κB, Non-Hodgkin’s Lymphoma, Peptide Inhibitor, Staudt, therapeutic
Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Application > Therapeutics, TherapeuticArea > Immunology